Annexin A1/FPR2 pathway modulates leukocyte function during Escherichia coli‐induced pneumonia to promote resolution of inflammation and restores lung function
Authors:
- Edvaldo S. LaraELEdvaldo S. Lara
- Antônio Felipe S. CarvalhoACAntônio Felipe S. Carvalho
- Camila CardosoCCCamila Cardoso
- Isabella ZaidanIZIsabella Zaidan
- Laís C. GrossiLGLaís C. Grossi
- Fernanda S. CarneiroFCFernanda S. Carneiro
- Erick Bryan S. LimaELErick Bryan S. Lima
- Adelson Heric A. MonteiroAMAdelson Heric A. Monteiro
- Rodrigo S. CaixetaRCRodrigo S. Caixeta
- Isabella L. AugustoIAIsabella L. Augusto
- Ana Clara M. Montuori‐AndradeAMAna Clara M. Montuori‐Andrade
- Lívia Cristina R. TeixeiraLTLívia Cristina R. Teixeira
- 1 April 2025
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (15) , 3539-3558
Abstract
Background and Purpose: Gram‐negative bacteria are the main causes of pneumonia in the nosocomial environment. Inflammation triggered during pneumonia is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination. Emerging data shows that annexin A1 (ANXA1) signalling through its receptor FPR2 promotes host resistance and resilience in preclinical models of infectious disease.Experimental Approach: Using a mouse model of Escherichia coli‐induced pneumonia, the role of ANXA1/FPR2 on key steps of inflammation resolution was evaluated.Key Results: Anxa1 and Fpr2/3 knockout mice, intranasally infected with E. coli, exhibited exacerbated neutrophilic inflammation, higher bacterial dissemination, decreased neutrophil apoptosis/efferocytosis counts in the airways and higher levels of inflammatory cytokines/chemokines coupled to marked lung damage and dysfunction, as compared to WT mice. Treatment of WT‐infected mice with the ANXA1 peptidomimetic, annexin I‐(2‐26), decreased inflammation, increased apoptosis/efferocytosis of neutrophils and improved bacterial clearance in the airways and lungs, resulting in an improvement of lung function. The pan‐caspase inhibitor Z‐VAD‐FMK prevented annexin I‐(2‐26)‐induced resolution of the neutrophilic inflammation, underlining neutrophil apoptosis as the main mechanism for annexin I‐(2‐26) promotion of resolution of E. coli pneumonia. In addition, annexin I‐(2‐26) treatment increased the numbers of airway macrophages of infected mice and promoted macrophage phagocytosis of E. coli in vitro.Conclusions and Implications: In summary, these findings highlight the role for ANXA1/FPR2 pathway as a nonredundant resolution mechanism for E. coli‐induced pneumonia and demonstrate that annexin I‐(2‐26) as a potential host‐directed therapeutic approach to treat infectious lung diseases.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (PQ‐310799/2022‐8 to L.P.S.)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ‐03221‐18 to L.P.S., BPD‐01010‐22 to L.P.S.)
This publication has 60 references indexed in Scilit:
- Annexin A1 improves immune responses and control of tissue parasitism during Leishmania amazonensis infection in BALB/c miceBiomedicine & Pharmacotherapy, 2024
- Glucocorticoids and COVID-19Pharmacological Research, 2022
- Novel Immunomodulatory Therapies for Respiratory Pathologies2022
- Lipid-Derived Mediators are Pivotal to Leukocyte and Lung Cell Responses in Sepsis and ARDSCell Biochemistry and Biophysics, 2021
- Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19Intensive Care Medicine, 2021
- Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseasesBiomedicine & Pharmacotherapy, 2021
- New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regenerationMolecular Aspects of Medicine, 2018
- Mimetic peptide AC2-26 of annexin A1 as a potential therapeutic agent to treat COPDInternational Immunopharmacology, 2018
- Annexin A1 promotes timely resolution of inflammation in murine goutEuropean Journal of Immunology, 2016
- Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen‐induced arthritisArthritis & Rheumatism, 2004